Home
Storia in 1 fonti
LifeSci Capital Remains a Buy on Maze Therapeutics, Inc. (MAZE)
LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Maze Therapeutics, Inc. today and set a price target of $57.00.Claim 55% Off Ti...
Raccontata da
markets.businessinsider.com
Timeline cronologica
- ·
LifeSci Capital Remains a Buy on Maze Therapeutics, Inc. (MAZE)
LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Maze Therapeutics, Inc. today and set a price target of $57.00.Claim 55% Off Ti...
- ·
LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)
LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on MoonLake Immunotherapeutics today and set a price target of $33.00.Claim 55% Of...
- ·
LifeSci Capital Remains a Buy on Perspective Therapeutics (CATX)
LifeSci Capital analyst Oliver McCammon maintained a Buy rating on Perspective Therapeutics today and set a price target of $15.00.Claim 55% Off...
- ·
LifeSci Capital Remains a Buy on Amylyx Pharmaceuticals Inc (AMLX)
In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Amylyx Pharmaceuticals Inc, with a price target of $24...